This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Appelmelk, B J Articles by de Graaff, J Search for Related Content PubMed PubMed Citation Articles by Appelmelk, B J Articles by de Graaff, J

 Previous Article  |  Next Article 

Infection and Immunity, August 1994, p. 3564-3567, Vol. 62, No. 8
0019-9567/1994/$04.00+0     DOI:

research-article

Recombinant human bactericidal/permeability-increasing protein (rBPI23) is a universal lipopolysaccharide-binding ligand.

Department of Medical Microbiology, Vrije Universiteit, Amsterdam, The Netherlands.

ABSTRACT

A recombinant 23-kDa protein (rBPI23) derived from human bactericidal/permeability-increasing protein (BPI) possesses potent endotoxin-neutralizing abilities in vitro and in vivo. Binding of rBPI23 to those endotoxins (lipopolysaccharides [LPSs]) encountered clinically would be a prerequisite for efficacy in decreasing mortality among patients suffering from gram-negative sepsis and shock, a disease state in which an etiological role for LPS has been implicated. rBPI23 binds well to lipid A (n = 7), to rough-mutant O-chain-deficient LPS (n = 18, Re to Ra chemotypes), to lipid A-core covalently linked to the O chain, to LPSs from clinically relevant serotypes (n = 100), and to bacterial cells (n = 88) of Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae, the species most often implicated in clinical gram-negative sepsis and shock. Significant binding of rBPI23 to these antigens took place at rBPI23 concentrations of 1 to 500 ng/ml (median, 16 to 32 ng/ml). Binding did not involve 3-deoxy-D-manno-octulosonate of the inner core. Determining the exact epitope recognized by rBPI23 would require further studies with synthetic lipid A substructures. The demonstrated ability of rBPI23 to universally bind LPS provides a sound basis for further testing of its endotoxin-neutralizing abilities, including clinical trials.

This article has been cited by other articles:

• Andra, J., Gutsmann, T., Garidel, P., Brandenburg, K. (2006). Invited review: Mechanisms of endotoxin neutralization by synthetic cationic compounds. Innate Immunity 12: 261-277 [Abstract]  
• Alexander, C., Rietschel, E. Th. (2001). Invited review: Bacterial lipopolysaccharides and innate immunity. Innate Immunity 7: 167-202 [Abstract]  
• David, S. A., Awasthi, S. K., Balaram, P. (2000). The role of polar and facial amphipathic character in determining lipopolysaccharide-binding properties in synthetic cationic peptides. Innate Immunity 6: 249-256 [Abstract]